Synchronous high-risk melanoma and lymphoid neoplasia

Melanoma Research

Volumn 11, Issue 5, 2001, Pages 517-522

  Cahill, R A ^a   McGreal, G ^a   Neary, P ^a   Redmond, H P ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

Immunotherapy; Interferon; Lymphoid neoplasia; Melanoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE DISSECTION; LYMPHATIC SYSTEM TUMOR; MALE; MELANOMA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT CONTRAINDICATION;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE SUSCEPTIBILITY; ENVIRONMENT; FEMALE; HUMANS; INCIDENCE; INTERFERON-ALPHA; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; RADIOTHERAPY; RISK FACTORS; ULTRAVIOLET RAYS;

EID: 0034776553     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200110000-00012     Document Type: Article

References (39)

1. Association of malignant melanoma and malignant lymphoma
2. Evidence of an association between non-Hodgkin's lymphoma and skin cancer
3. The association between melanoma, lymphoma and other primary neoplasms
4. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and other skin cancers
5. Are malignant melanoma patients at higher risk of a second cancer?
6. Second cancers following non-Hodgkin's lymphoma
7. Second cancers in patients with chronic lymphocytic leukaemia
8. Second cancers among long-term survivors of non-Hodgkin's lymphoma
9. Have increases in solar ultraviolet exposure contributed to the rise in incidence of non-Hodgkin's lymphoma?
10. Non-Hodgkin's lymphoma and skin malignancies - Shared aetiology?
11. Cutaneous melanoma
12. The current situation with regard to human melanoma and genetic inferences
13. The role of genetic instability, adhesion, cell motility and immune escape mechanisms in melanoma progression
14. The PTEN suppressor gene and malignant melanona
15. Distinctive chromosomal abnormalities in histological subtypes of non-Hodgkin's lymphoma
16. Chromosomal abnormalities in indolent lymphoma
17. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma
18. Risk of cancer in renal transplants recipients
19. Association of non-acquired immunodeficiency syndrome-defining cancers with human immunodeficiency virus infection
20. Malignant melanoma in an HIV infected man: A case report and literature review
21. Epidemiologic study on Yusho, a poisoning caused by ingestion of rice oil contaminated with a commercial brand of polychlorinated biphenyls
22. Melanoma and sun exposure: Contrasts between intermittent and chronic sun exposure
23. Immune surveillance and sunlight-induced skin cancer
24. Deficient antigen presentation and Ts induction are separate effects of ultraviolet radiation
25. Chemotherapy for non-Hodgkin's lymphoma
26. Systemic therapy in melanoma
27. Current therapy for malignant melanoma
28. Current role of radiotherapy in Hodgkin's and non-Hodgkin's lymphoma
29. Adjuvant therapy for melanoma
30. Medical management of stage 4 malignant melanoma. Medical issues
31. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
32. Interferon adjuvant therapy of melanoma
33. Randomised trial of interferon 2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
34. Adjuvant IFNα2 therapy of melanoma
35. A quality-of-life-adjusted survival analysis of interferon alfa-2b in high-risk resected cutaneous melanoma: Eastern Cooperative Oncology Group Study (E1684)
36. Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma
37. Immunotherapy for non-Hodgkin's lymphoma
38. Role of interferon alpha-2b in the induction of and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective multicentre trial with double randomisation